Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Collegium Pharmaceutical, Inc. - Common Stock
(NQ:
COLL
)
46.21
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Collegium Pharmaceutical, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Collegium Announces $25 Million Accelerated Share Repurchase Program
May 12, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Pharmaceutical (NASDAQ:COLL) Exceeds Q1 Expectations
May 08, 2025
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 22.7% year on year to $177.8 million. The company...
Via
StockStory
Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress
May 08, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Earnings Scheduled For May 8, 2025
↗
May 08, 2025
Via
Benzinga
Earnings Scheduled For February 27, 2025
↗
February 27, 2025
Via
Benzinga
A Preview Of Collegium Pharmaceutical's Earnings
↗
November 06, 2024
Via
Benzinga
Collegium Pharmaceutical (COLL) Q1 Earnings: What To Expect
May 07, 2025
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting earnings tomorrow after market close. Here’s what to look for.
Via
StockStory
3 Healthcare Stocks That Concern Us
April 28, 2025
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID...
Via
StockStory
Topics
Stocks
Collegium to Report First Quarter 2025 Financial Results on May 8, 2025
April 24, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
2 Reasons to Watch COLL and 1 to Stay Cautious
April 14, 2025
Collegium Pharmaceutical’s stock price has taken a beating over the past six months, shedding 31.6% of its value and falling to $26.01 per share. This might have investors contemplating their next...
Via
StockStory
What Analysts Are Saying About Collegium Pharmaceutical Stock
↗
April 09, 2025
Via
Benzinga
A Look Back at Branded Pharmaceuticals Stocks’ Q4 Earnings: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Pack
April 02, 2025
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Collegium Pharmaceutical...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference
April 01, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine’s Annual Meeting
March 27, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
March 26, 2025
From
Avalo Therapeutics
Via
GlobeNewswire
Forecasting The Future: 4 Analyst Projections For Collegium Pharmaceutical
↗
March 24, 2025
Via
Benzinga
Q4 Earnings Highs And Lows: Royalty Pharma (NASDAQ:RPRX) Vs The Rest Of The Branded Pharmaceuticals Stocks
March 21, 2025
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Royalty Pharma (NASDAQ:RPRX)...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Collegium Announces Updates to its Board of Directors and Executive Leadership Team
March 17, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care
March 10, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium to Participate in Upcoming Investor Conferences
March 04, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Pharmaceutical’s (NASDAQ:COLL) Q4 Sales Top Estimates, Stock Jumps 14.1%
February 27, 2025
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 21.5% year on year to $181.9 million. The company...
Via
StockStory
Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results
February 27, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Pharmaceutical (COLL) Reports Earnings Tomorrow: What To Expect
February 26, 2025
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting earnings tomorrow after the bell. Here’s what to look for.
Via
StockStory
Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025
February 13, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Appoints Nancy S. Lurker to its Board of Directors
February 05, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium's Revenue Outlook And CNS Expansion Signal Undervalued Opportunity, Says Needham
↗
January 10, 2025
Needham analyst upgrades Collegium Pharmaceutical to Buy with a $46 target, citing strong 2025 guidance, growth potential, and undervaluation.
Via
Benzinga
Collegium Provides 2025 Financial Guidance and Business Update
January 08, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium to Participate in Upcoming Investor Conferences
November 12, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Reports Record Third Quarter 2024 Financial Results
November 07, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Appoints Vikram Karnani as Chief Executive Officer
November 07, 2024
Vikram Karnani is a Proven Industry Leader with Extensive Experience Growing Commercial Biopharmaceutical Businesses
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
